MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033
Market Introduction
Minimal residual disease (MRD) testing is a technique used to detect and quantify the small number of cancer cells that remain in a patient's body after treatment. It involves sensitive technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to identify residual disease at a molecular level. MRD testing is clinically important as it helps to monitor treatment response, predict relapse risk, guide personalized therapies, and serve as an endpoint in clinical trials. By identifying and addressing MRD, healthcare providers can strive for better treatment outcomes and improved patient survival rates.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033. The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis. In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing. Healthcare providers and researchers are recognizing this trend and striving to meet the expectations of patients by integrating MRD testing into clinical practice.
Market Lifecycle Stage
The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients. This market focuses on technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry that enable the detection and quantification of minimal residual disease (MRD) in cancer patients. With its clinical significance in treatment response monitoring, prognostic assessment, and personalized treatment approaches, the minimal residual testing market offers immense opportunities for diagnostic companies, pharmaceutical manufacturers, and research institutions to develop innovative solutions and contribute to improving patient outcomes and survival rates.
Industrial Impact
Minimal residual disease (MRD) assessment is an adjunctive method used to identify exceedingly low levels of blood cancer cells and solid tumors after the treatment of conditions such as acute and chronic leukemia, lymphoma, and multiple myeloma. MRD refers specifically to the small population of cancer cells that remain in the body despite achieving complete remission (CR) following treatments such as chemotherapy or stem cell transplantation. Detecting these residual cancer cells, which often go unnoticed through traditional microscopic examination of the bone marrow, requires more sensitive techniques for accurate evaluation.
By enabling early detection, guiding treatment decisions, and providing a sensitive assessment of minimal residual disease (MRD) testing contributes to improved patient outcomes, supports precision medicine approaches, and plays a vital role in research and clinical trials. Furthermore, the rising incidence of cancer has spurred research and technological advancements in the field of MRD testing. Efforts to enhance the sensitivity, accuracy, and efficiency of MRD testing methods have been driven by the need to address the diagnostic challenges posed by increasing cancer rates. These aforementioned advancements in minimal residual disease testing have resulted in the development of new technologies, improved laboratory protocols, and novel approaches.
In recent years, in March 2023, Providence and GRAIL strengthened their collaboration to enhance the availability of the Galleri multi-cancer early detection screening, with an intent to broaden its accessibility. Similarly, in December 2022, IDT (Integrated DNA Technologies) acquired the ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation. This acquisition of the NGS research assays is in line with Integrated DNA Technologies, Inc.'s goal of expansion of scientific discovery and establishing itself as a prominent provider of oncology research solutions in the industry.
Market Segmentation:
Segmentation 1: by Technology
The global MRD testing market is led by flow cytometry in the technology segment, with a 41.14% share in 2022. The market growth is attributed to recent technological innovations in multiparametric flow cytometry, such as the development of high-sensitivity 10-color and 12-color flow cytometry assay for the identification of leukemia-associated phenotypes (LAPs) and estimation of the prognostic significance of treatment in MRD patients.
MRD testing uses highly sensitive methods such as flow cytometry, PCR, NGS, and other methods. These tests use bone marrow samples and/or peripheral blood cells (taken through a vein). Significant advancements are being witnessed in the development of highly sensitive, quantitative, and multiplex assays. Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing. Techniques such as karyotyping and classical microscopy have lesser value in MRD detection due to their low sensitivity.
Segmentation 2: by Target Detection
The global MRD testing market is estimated to be led by the solid tumor in the target detection segment, with a share of 15.09% in 2022, owing to the increasing number of companies entering the market with a focus on solid tumor based MRD testing. The assessment of minimal residual disease (MRD) is a crucial prognostic indicator, and the application of circulating tumor DNA (ctDNA) analysis for evaluating MRD in solid tumors after curative treatment and prior to disease recurrence has shown great therapeutic potential. This promising advancement is a key driving force behind the growth of ctDNA analysis in the field.
Segmentation 3: by End User
The global MRD testing market is estimated to be led by the hospitals and specialty clinics in the end user segment, with a share of 44.38% in 2022. Hospitals are at the forefront of providing MRD testing kits and services to detect residual cells in solid tumors and hematological malignancies in routine healthcare procedures. There is high adoption of various testing assays by hospitals, particularly in the field of oncology. Moreover, hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific (APAC), have incorporated extensive molecular diagnostics test portfolios to provide superior care to patients. Other end users, such as outpatient clinics and cancer clinics, also contribute significantly to the global MRD testing market.
Segmentation 4: by Region
Recent Developments in the MRD Testing Market
In April 2023, Quest Diagnostics acquired Haystack Oncology, expanding its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition aimed to enhance personalized cancer care by offering highly sensitive diagnostic capabilities.
In April 2023, Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel, a pioneering cancer research testing solution that has been enhanced and fine-tuned to include a broader range of single nucleotide variant (SNV) and indel coverage.
In April 2023, Adaptive Biotechnologies collaborated on a translational partnership with Takeda to employ its clonoSEQ assay throughout Takeda's range of hematologic malignancy treatments, enabling the measurement of minimal residual disease.
Demand – Drivers and Limitations
Market Demand Drivers:
Advancements in the Development of Companion Diagnostics
Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The technology segment helps the reader understand the different types of technologies available for currently available tests and their potential globally. Moreover, the study provides the reader with a detailed understanding of the global MRD testing market by end-user application (hospitals and specialty clinics, research institutions, diagnostic laboratories, and other end users), by technology (flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and Other technologies), and by target detection (leukemia, lymphoma, and solid tumor).
Growth/Marketing Strategy: The MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market. For instance, in April 2023, Bio-Rad Laboratories is enhancing the pace of measurable residual disease (MRD) research by engaging in over six partnerships with institutions and companies, utilizing their latest QX600 Droplet Digital PCR System.
Competitive Strategy: Key players in the MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top segment players leading in the market include 11 public companies that capture around 73.33% of the presence in the market. On the other hand, there are four private players, including Invivoscribe, Inc. and Mission Bio, among others, which account for approximately 26.67% of the presence in the market.
Key Companies Profiled:
Minimal residual disease (MRD) testing is a technique used to detect and quantify the small number of cancer cells that remain in a patient's body after treatment. It involves sensitive technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry to identify residual disease at a molecular level. MRD testing is clinically important as it helps to monitor treatment response, predict relapse risk, guide personalized therapies, and serve as an endpoint in clinical trials. By identifying and addressing MRD, healthcare providers can strive for better treatment outcomes and improved patient survival rates.
The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033. The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis. In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing. Healthcare providers and researchers are recognizing this trend and striving to meet the expectations of patients by integrating MRD testing into clinical practice.
Market Lifecycle Stage
The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients. This market focuses on technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry that enable the detection and quantification of minimal residual disease (MRD) in cancer patients. With its clinical significance in treatment response monitoring, prognostic assessment, and personalized treatment approaches, the minimal residual testing market offers immense opportunities for diagnostic companies, pharmaceutical manufacturers, and research institutions to develop innovative solutions and contribute to improving patient outcomes and survival rates.
Industrial Impact
Minimal residual disease (MRD) assessment is an adjunctive method used to identify exceedingly low levels of blood cancer cells and solid tumors after the treatment of conditions such as acute and chronic leukemia, lymphoma, and multiple myeloma. MRD refers specifically to the small population of cancer cells that remain in the body despite achieving complete remission (CR) following treatments such as chemotherapy or stem cell transplantation. Detecting these residual cancer cells, which often go unnoticed through traditional microscopic examination of the bone marrow, requires more sensitive techniques for accurate evaluation.
By enabling early detection, guiding treatment decisions, and providing a sensitive assessment of minimal residual disease (MRD) testing contributes to improved patient outcomes, supports precision medicine approaches, and plays a vital role in research and clinical trials. Furthermore, the rising incidence of cancer has spurred research and technological advancements in the field of MRD testing. Efforts to enhance the sensitivity, accuracy, and efficiency of MRD testing methods have been driven by the need to address the diagnostic challenges posed by increasing cancer rates. These aforementioned advancements in minimal residual disease testing have resulted in the development of new technologies, improved laboratory protocols, and novel approaches.
In recent years, in March 2023, Providence and GRAIL strengthened their collaboration to enhance the availability of the Galleri multi-cancer early detection screening, with an intent to broaden its accessibility. Similarly, in December 2022, IDT (Integrated DNA Technologies) acquired the ArcherDX Next Generation Sequencing Research Assays from Invitae Corporation. This acquisition of the NGS research assays is in line with Integrated DNA Technologies, Inc.'s goal of expansion of scientific discovery and establishing itself as a prominent provider of oncology research solutions in the industry.
Market Segmentation:
Segmentation 1: by Technology
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Other Technologies
The global MRD testing market is led by flow cytometry in the technology segment, with a 41.14% share in 2022. The market growth is attributed to recent technological innovations in multiparametric flow cytometry, such as the development of high-sensitivity 10-color and 12-color flow cytometry assay for the identification of leukemia-associated phenotypes (LAPs) and estimation of the prognostic significance of treatment in MRD patients.
MRD testing uses highly sensitive methods such as flow cytometry, PCR, NGS, and other methods. These tests use bone marrow samples and/or peripheral blood cells (taken through a vein). Significant advancements are being witnessed in the development of highly sensitive, quantitative, and multiplex assays. Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing. Techniques such as karyotyping and classical microscopy have lesser value in MRD detection due to their low sensitivity.
Segmentation 2: by Target Detection
- Leukemia
- Lymphoma
- Solid Tumor
The global MRD testing market is estimated to be led by the solid tumor in the target detection segment, with a share of 15.09% in 2022, owing to the increasing number of companies entering the market with a focus on solid tumor based MRD testing. The assessment of minimal residual disease (MRD) is a crucial prognostic indicator, and the application of circulating tumor DNA (ctDNA) analysis for evaluating MRD in solid tumors after curative treatment and prior to disease recurrence has shown great therapeutic potential. This promising advancement is a key driving force behind the growth of ctDNA analysis in the field.
Segmentation 3: by End User
- Hospitals and Speciality Clinics
- Research Institutions
- Diagnostic Laboratories
- Other End Users
The global MRD testing market is estimated to be led by the hospitals and specialty clinics in the end user segment, with a share of 44.38% in 2022. Hospitals are at the forefront of providing MRD testing kits and services to detect residual cells in solid tumors and hematological malignancies in routine healthcare procedures. There is high adoption of various testing assays by hospitals, particularly in the field of oncology. Moreover, hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific (APAC), have incorporated extensive molecular diagnostics test portfolios to provide superior care to patients. Other end users, such as outpatient clinics and cancer clinics, also contribute significantly to the global MRD testing market.
Segmentation 4: by Region
- North America - U.S. and Canada
- Europe - Germany, France, U.K., Italy, Spain, and Rest-of-Europe
- Asia-Pacific - China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
- Latin America and Middle East - Brazil, Mexico, Saudi Arabia, and Rest-of-Latin America and Middle East
- Rest-of-the-World (RoW)
Recent Developments in the MRD Testing Market
In April 2023, Quest Diagnostics acquired Haystack Oncology, expanding its oncology portfolio with the inclusion of advanced liquid biopsy technology. This addition aimed to enhance personalized cancer care by offering highly sensitive diagnostic capabilities.
In April 2023, Integrated DNA Technologies launched the Archer FUSIONPlex Core Solid Tumor Panel, a pioneering cancer research testing solution that has been enhanced and fine-tuned to include a broader range of single nucleotide variant (SNV) and indel coverage.
In April 2023, Adaptive Biotechnologies collaborated on a translational partnership with Takeda to employ its clonoSEQ assay throughout Takeda's range of hematologic malignancy treatments, enabling the measurement of minimal residual disease.
Demand – Drivers and Limitations
Market Demand Drivers:
- Advent of MRD Testing and its Awareness among Consumers
- Increasing Incidence of Cancer Cases Demanding MRD Testing
- Rise in Administration of Solid Tumor Diagnosis in MRD Testing Ecosystem
- Expanding Medicare Coverage for MRD Testing
- Early-Risk of Progression and Relapse due to MRD Negative Results
- Substantially High Cost of MRD Testing
Advancements in the Development of Companion Diagnostics
Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The technology segment helps the reader understand the different types of technologies available for currently available tests and their potential globally. Moreover, the study provides the reader with a detailed understanding of the global MRD testing market by end-user application (hospitals and specialty clinics, research institutions, diagnostic laboratories, and other end users), by technology (flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and Other technologies), and by target detection (leukemia, lymphoma, and solid tumor).
Growth/Marketing Strategy: The MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market. For instance, in April 2023, Bio-Rad Laboratories is enhancing the pace of measurable residual disease (MRD) research by engaging in over six partnerships with institutions and companies, utilizing their latest QX600 Droplet Digital PCR System.
Competitive Strategy: Key players in the MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
The top segment players leading in the market include 11 public companies that capture around 73.33% of the presence in the market. On the other hand, there are four private players, including Invivoscribe, Inc. and Mission Bio, among others, which account for approximately 26.67% of the presence in the market.
Key Companies Profiled:
- Adaptive Biotechnologies
- ARUP Laboratories
- Bio-Rad Laboratories, Inc.
- Cergentis B.V.
- F. Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Mission Bio, Inc.
- ICON plc
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- OPKO Health, Inc.
- Quest Diagnostics Incorporated
- Sysmex Corporation
1 MARKETS
1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in the Report
1.4 Research Methodology
1.4.1 Global MRD Testing Market: Research Methodology
1.4.2 Data Sources
1.5 Market Estimation Model
1.5.1 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 MRD Testing Workflow Analysis
2.2 MRD Testing: Solid Tumor vs. Hematological Malignancy
2.3 Evolution of MRD Testing
2.4 Market Footprint
2.5 Market Size and Future Growth Potential
3 INDUSTRY INSIGHTS
3.1 Legal and Regulatory Framework of MRD Tests
3.1.1 U.S.
3.1.2 Europe
3.1.3 Asia-Pacific
3.2 Reimbursement Scenario
3.2.1 North America
3.2.2 European Union
3.2.3 Asia-Pacific
3.3 Supply Chain Analysis
3.3.1 For Laboratory Developed Tests (LDTs)
3.3.2 For In-Vitro Diagnostics (IVDs)
4 MARKET DYNAMICS
4.1 Overview
4.2 Market Drivers
4.2.1 Advent of MRD Testing and its Awareness among Consumers
4.2.2 Increasing Incidence of Cancer Cases Demanding MRD Testing
4.2.3 Rise in Administration of Solid Tumor Diagnosis in MRD Testing Ecosystem
4.2.4 Expanding Medicare Coverage for MRD Testing
4.3 Market Challenges
4.3.1 Early-Risk of Progression and Relapse due to MRD Negative Results
4.3.2 Substantially High Cost of MRD Testing
4.4 Market Opportunities
4.4.1 Advancements in the Development of Companion Diagnostics
4.4.2 Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions
5 COMPETITIVE INSIGHTS
5.1 Overview
5.2 Key Strategies and Developments
5.2.1 Synergistic Activities
5.2.2 Product Launches and Product Approvals
5.2.3 Business Expansion
5.2.4 Mergers and Acquisitions
5.2.5 Funding and Other Activities
5.3 Company Share Analysis
5.4 Growth Share Analysis
6 GLOBAL MINIMAL RESIDUAL TESTING MARKET (BY TECHNOLOGY), 2022-2033
6.1 Overview
6.2 Flow Cytometry
6.3 Polymerase Chain Reaction (PCR)
6.4 Next-Generation Sequencing (NGS)
6.5 Other Technologies
7 GLOBAL MINIMAL RESIDUAL TESTING MARKET (BY TARGET DETECTION), 2022-2033
7.1 Overview
7.2 Leukemia
7.2.1 Multiple Myeloma
7.2.2 Acute Lymphoblastic Leukemia
7.2.3 Chronic Lymphocytic Leukemia
7.2.4 Acute Myeloid Leukemia
7.2.5 Chronic Myeloid Leukemia
7.2.6 Other Leukemia
7.3 Lymphoma
7.3.1 Non-Hodgkin’s Lymphoma
7.3.2 Hodgkin’s Lymphoma
7.4 Solid Tumor
7.4.1 Colorectal Cancer
7.4.2 Breast Cancer
7.4.3 Lung Cancer
7.4.4 Other Cancer
8 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET (BY END USER), 2022-2033
8.1 Overview
8.2 Hospitals and Specialty Clinics
8.3 Diagnostic Laboratories
8.4 Research Institutions
8.5 Others
9 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET (BY REGION), 2022-2033
9.1 Overview
9.2 North America
9.2.1 North America MRD Testing Market, by End User
9.2.2 North America MRD Testing Market, by Country
9.3 Europe
9.3.1 Europe MRD Testing Market, by End User
9.3.2 Europe MRD Testing Market, by Country
9.4 Asia-Pacific
9.4.1 Asia-Pacific MRD Testing Market, by End User
9.4.2 Asia-Pacific MRD Testing Market, by Country
9.5 Latin America and Middle East
9.5.1 Latin America and Middle East MRD Testing Market, by End User
9.5.2 Latin America and Middle East MRD Testing Market, by Country
9.6 Rest-of-the-World (RoW)
9.6.1 Rest-of-the-World MRD Testing Market, by End User
10 COMPANY PROFILES
10.1 Overview
10.2 MRD Testing Ecosystem Active Players
10.3 Adaptive Biotechnologies
10.3.1 Company Overview
10.3.2 Role of Adaptive Biotechnologies in the Global MRD Testing Market
10.3.3 Financials
10.3.4 Recent Developments
10.3.5 Analyst Perspective
10.4 ARUP Laboratories
10.4.1 Company Overview
10.4.2 Role of ARUP Laboratories in the Global MRD Testing Market
10.4.3 Recent Developments
10.4.4 Analyst Perspective
10.5 Bio-Rad Laboratories, Inc.
10.5.1 Company Overview
10.5.2 Role of Bio-Rad Laboratories, Inc. in the Global MRD Testing Market
10.5.3 Financials
10.5.4 Recent Developments
10.5.5 Analyst Perspective
10.6 Cergentis B.V.
10.6.1 Company Overview
10.6.2 Role of Cergentis B.V. in the Global MRD Testing Market
10.6.3 Analyst Perspective
10.7 F. Hoffmann-La Roche Ltd
10.7.1 Company Overview
10.7.2 Role of F. Hoffmann-La Roche Ltd in the Global MRD Testing Market
10.7.3 Financials
10.7.1 Recent Developments
10.7.2 Analyst Perspective
10.8 Guardant Health, Inc.
10.8.1 Company Overview
10.8.2 Role of Guardant Health, Inc. in the Global MRD Testing Market
10.8.3 Financials
10.8.4 Recent Developments
10.8.5 Analyst Perspective
10.9 Invivoscribe, Inc.
10.9.1 Company Overview
10.9.2 Role of Invivoscribe, Inc. in the Global MRD Testing Market
10.9.3 Analyst Perspective
10.1 Laboratory Corporation of America Holdings
10.10.1 Company Overview
10.10.2 Role of Laboratory Corporation of America Holdings in the Global MRD Testing Market
10.10.3 Financials
10.10.4 Recent Developments
10.10.5 Analyst Perspective
10.11 Mission Bio, Inc.
10.11.1 Company Overview
10.11.2 Role of Mission Bio, Inc. in the Global Minimal Residual Disease Testing Market
10.11.3 Recent Developments
10.11.4 Analyst Perspective
10.12 ICON plc
10.12.1 Company Overview
10.12.2 Role of ICON plc in the Global MRD Testing Market
10.12.3 Financials
10.12.4 Analyst Perspective
10.13 Natera, Inc.
10.13.1 Company Overview
10.13.2 Role of Natera, Inc. in the Global MRD Testing Market
10.13.3 Financials
10.13.4 Recent Developments
10.13.5 Analyst Perspective
10.14 NeoGenomics Laboratories, Inc.
10.14.1 Company Overview
10.14.2 Role of NeoGenomics Laboratories, Inc. in the Global MRD Testing Market
10.14.3 Financials
10.14.4 Recent Developments
10.14.5 Analyst Perspective
10.15 OPKO Health, Inc.
10.15.1 Company Overview
10.15.2 Role of OPKO Health, Inc. in the Global MRD Testing Market
10.15.3 Financials
10.15.4 Recent Developments
10.15.5 Analyst Perspective
10.16 Quest Diagnostics Incorporated
10.16.1 Company Overview
10.16.2 Role of Quest Diagnostics Incorporated in the Global MRD Testing Market
10.16.3 Financials
10.16.4 Recent Developments
10.16.5 Analyst Perspective
10.17 Sysmex Corporation
10.17.1 Company Overview
10.17.2 Role of Sysmex Corporation in the Global MRD Testing Market
10.17.3 Financials
10.17.4 Analyst Perspective
1.1 Product Definition
1.2 Inclusion and Exclusion Criteria
1.3 Market Scope
1.3.1 Scope of the Study
1.3.2 Key Questions Answered in the Report
1.4 Research Methodology
1.4.1 Global MRD Testing Market: Research Methodology
1.4.2 Data Sources
1.5 Market Estimation Model
1.5.1 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 MRD Testing Workflow Analysis
2.2 MRD Testing: Solid Tumor vs. Hematological Malignancy
2.3 Evolution of MRD Testing
2.4 Market Footprint
2.5 Market Size and Future Growth Potential
3 INDUSTRY INSIGHTS
3.1 Legal and Regulatory Framework of MRD Tests
3.1.1 U.S.
3.1.2 Europe
3.1.3 Asia-Pacific
3.2 Reimbursement Scenario
3.2.1 North America
3.2.2 European Union
3.2.3 Asia-Pacific
3.3 Supply Chain Analysis
3.3.1 For Laboratory Developed Tests (LDTs)
3.3.2 For In-Vitro Diagnostics (IVDs)
4 MARKET DYNAMICS
4.1 Overview
4.2 Market Drivers
4.2.1 Advent of MRD Testing and its Awareness among Consumers
4.2.2 Increasing Incidence of Cancer Cases Demanding MRD Testing
4.2.3 Rise in Administration of Solid Tumor Diagnosis in MRD Testing Ecosystem
4.2.4 Expanding Medicare Coverage for MRD Testing
4.3 Market Challenges
4.3.1 Early-Risk of Progression and Relapse due to MRD Negative Results
4.3.2 Substantially High Cost of MRD Testing
4.4 Market Opportunities
4.4.1 Advancements in the Development of Companion Diagnostics
4.4.2 Rising Number of Clinical Trials in Prolonged MRD-Negative Treatment Decisions
5 COMPETITIVE INSIGHTS
5.1 Overview
5.2 Key Strategies and Developments
5.2.1 Synergistic Activities
5.2.2 Product Launches and Product Approvals
5.2.3 Business Expansion
5.2.4 Mergers and Acquisitions
5.2.5 Funding and Other Activities
5.3 Company Share Analysis
5.4 Growth Share Analysis
6 GLOBAL MINIMAL RESIDUAL TESTING MARKET (BY TECHNOLOGY), 2022-2033
6.1 Overview
6.2 Flow Cytometry
6.3 Polymerase Chain Reaction (PCR)
6.4 Next-Generation Sequencing (NGS)
6.5 Other Technologies
7 GLOBAL MINIMAL RESIDUAL TESTING MARKET (BY TARGET DETECTION), 2022-2033
7.1 Overview
7.2 Leukemia
7.2.1 Multiple Myeloma
7.2.2 Acute Lymphoblastic Leukemia
7.2.3 Chronic Lymphocytic Leukemia
7.2.4 Acute Myeloid Leukemia
7.2.5 Chronic Myeloid Leukemia
7.2.6 Other Leukemia
7.3 Lymphoma
7.3.1 Non-Hodgkin’s Lymphoma
7.3.2 Hodgkin’s Lymphoma
7.4 Solid Tumor
7.4.1 Colorectal Cancer
7.4.2 Breast Cancer
7.4.3 Lung Cancer
7.4.4 Other Cancer
8 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET (BY END USER), 2022-2033
8.1 Overview
8.2 Hospitals and Specialty Clinics
8.3 Diagnostic Laboratories
8.4 Research Institutions
8.5 Others
9 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET (BY REGION), 2022-2033
9.1 Overview
9.2 North America
9.2.1 North America MRD Testing Market, by End User
9.2.2 North America MRD Testing Market, by Country
9.3 Europe
9.3.1 Europe MRD Testing Market, by End User
9.3.2 Europe MRD Testing Market, by Country
9.4 Asia-Pacific
9.4.1 Asia-Pacific MRD Testing Market, by End User
9.4.2 Asia-Pacific MRD Testing Market, by Country
9.5 Latin America and Middle East
9.5.1 Latin America and Middle East MRD Testing Market, by End User
9.5.2 Latin America and Middle East MRD Testing Market, by Country
9.6 Rest-of-the-World (RoW)
9.6.1 Rest-of-the-World MRD Testing Market, by End User
10 COMPANY PROFILES
10.1 Overview
10.2 MRD Testing Ecosystem Active Players
10.3 Adaptive Biotechnologies
10.3.1 Company Overview
10.3.2 Role of Adaptive Biotechnologies in the Global MRD Testing Market
10.3.3 Financials
10.3.4 Recent Developments
10.3.5 Analyst Perspective
10.4 ARUP Laboratories
10.4.1 Company Overview
10.4.2 Role of ARUP Laboratories in the Global MRD Testing Market
10.4.3 Recent Developments
10.4.4 Analyst Perspective
10.5 Bio-Rad Laboratories, Inc.
10.5.1 Company Overview
10.5.2 Role of Bio-Rad Laboratories, Inc. in the Global MRD Testing Market
10.5.3 Financials
10.5.4 Recent Developments
10.5.5 Analyst Perspective
10.6 Cergentis B.V.
10.6.1 Company Overview
10.6.2 Role of Cergentis B.V. in the Global MRD Testing Market
10.6.3 Analyst Perspective
10.7 F. Hoffmann-La Roche Ltd
10.7.1 Company Overview
10.7.2 Role of F. Hoffmann-La Roche Ltd in the Global MRD Testing Market
10.7.3 Financials
10.7.1 Recent Developments
10.7.2 Analyst Perspective
10.8 Guardant Health, Inc.
10.8.1 Company Overview
10.8.2 Role of Guardant Health, Inc. in the Global MRD Testing Market
10.8.3 Financials
10.8.4 Recent Developments
10.8.5 Analyst Perspective
10.9 Invivoscribe, Inc.
10.9.1 Company Overview
10.9.2 Role of Invivoscribe, Inc. in the Global MRD Testing Market
10.9.3 Analyst Perspective
10.1 Laboratory Corporation of America Holdings
10.10.1 Company Overview
10.10.2 Role of Laboratory Corporation of America Holdings in the Global MRD Testing Market
10.10.3 Financials
10.10.4 Recent Developments
10.10.5 Analyst Perspective
10.11 Mission Bio, Inc.
10.11.1 Company Overview
10.11.2 Role of Mission Bio, Inc. in the Global Minimal Residual Disease Testing Market
10.11.3 Recent Developments
10.11.4 Analyst Perspective
10.12 ICON plc
10.12.1 Company Overview
10.12.2 Role of ICON plc in the Global MRD Testing Market
10.12.3 Financials
10.12.4 Analyst Perspective
10.13 Natera, Inc.
10.13.1 Company Overview
10.13.2 Role of Natera, Inc. in the Global MRD Testing Market
10.13.3 Financials
10.13.4 Recent Developments
10.13.5 Analyst Perspective
10.14 NeoGenomics Laboratories, Inc.
10.14.1 Company Overview
10.14.2 Role of NeoGenomics Laboratories, Inc. in the Global MRD Testing Market
10.14.3 Financials
10.14.4 Recent Developments
10.14.5 Analyst Perspective
10.15 OPKO Health, Inc.
10.15.1 Company Overview
10.15.2 Role of OPKO Health, Inc. in the Global MRD Testing Market
10.15.3 Financials
10.15.4 Recent Developments
10.15.5 Analyst Perspective
10.16 Quest Diagnostics Incorporated
10.16.1 Company Overview
10.16.2 Role of Quest Diagnostics Incorporated in the Global MRD Testing Market
10.16.3 Financials
10.16.4 Recent Developments
10.16.5 Analyst Perspective
10.17 Sysmex Corporation
10.17.1 Company Overview
10.17.2 Role of Sysmex Corporation in the Global MRD Testing Market
10.17.3 Financials
10.17.4 Analyst Perspective
LIST OF FIGURES
Figure 1: Global MRD Testing Market, $Billion, 2022 and 2033
Figure 2: Share of Global MRD Testing Market (by Technology), $Billion, 2022 and 2033
Figure 3: Share of Global MRD Testing Market (by Target Detection), $Billion, 2022 and 2033
Figure 4: Share of Global MRD Testing Market (by End User), $Billion, 2022 and 2033
Figure 5: Share of Global MRD Testing Market (by Region), 2022
Figure 6: Global MRD Testing Market Segmentation
Figure 7: Global MRD Testing Market: Research Methodology
Figure 8: Primary Research Methodology
Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Top-Down Approach (Segment-Wise Analysis)
Figure 11: MRD Testing Workflow
Figure 12: Evolution of the MRD Testing Market
Figure 13: Global MRD Testing Market Potential, $Billion, 2022-2033
Figure 14: Biomarker Evaluation and Evidentiary Considerations
Figure 15: Regulatory Submissions for the Use of Minimal Residual Disease as a Biomarker
Figure 16: Laboratory Methods for MRD Detection
Figure 17: Methods to Achieve Coverage
Figure 18: Supply Chain Analysis of Laboratory-Developed Tests
Figure 19: Supply Chain Analysis of In-Vitro Diagnostics
Figure 20: Global MRD Testing Market Dynamics
Figure 21: Growth of MRD Solutions Showcasing Increasing Number of Tests
Figure 22: Estimated New Cancer Cases and Deaths in the U.S., 2022
Figure 23: Patents Related to Companion Diagnostics Products Involved in MRD Testing, 2019-2023
Figure 24: Clinical Trials Undertaken by Adaptive Biotechnologies for MRD Testing, 2022
Figure 25: Share of Key Developments and Strategies, January 2020-May 2023
Figure 26: Share of Synergistic Activities (by Company), January 2020- May 2023
Figure 27: Share of Product Launches and Product Approvals (by Company), January 2020- May 2023
Figure 28: Share of Business Expansion (by Company), January 2020-May 2023
Figure 29: Merger and Acquisition (by Company), January 2020- May 2023
Figure 30: Share of Funding and Other Activities (by Company), January 2020- May 2023
Figure 31: Global MRD Testing Market, Company Share Analysis, 2022
Figure 32: Global MRD Testing Market, Growth Share Analysis, (by Technology), 2023-2033
Figure 33: Global MRD Testing Market (by Technology), $Billion, 2022-2033
Figure 34: MRD Detection by Multiparametric Flow Cytometry (MFC)
Figure 35: Global MRD Testing Market (Flow Cytometry), $Billion, 2022-2033
Figure 36: Global MRD Testing Market (Flow Cytometry), Thousand Units, 2022-2033
Figure 37: Global Minimal Residual Disease Testing Market (PCR), $Billion, 2022-2033
Figure 38: Global MRD Testing Market (PCR), Thousand Units, 2022-2033
Figure 39: Global MRD Testing Market (NGS), $Billion, 2022-2033
Figure 40: High-Throughput Sequencing Workflow for MRD Monitoring
Figure 41: Global MRD Testing Market (NGS), Thousand Units, 2022-2033
Figure 42: Global MRD Testing Market (Other Technologies), $Billion, 2022-2033
Figure 43: Global MRD Testing Market (Other Technologies), Thousand Units, 2022-2033
Figure 44: Global MRD Testing Market (by Target Detection)
Figure 45: Global MRD Testing Market (by Target Detection), $Billion, 2022-2033
Figure 46: Global MRD Testing Market (Leukemia), $Billion, 2022-2033
Figure 47: Global MRD Testing Market (Leukemia), Units, 2022-2033
Figure 48: Global MRD Testing Market (Multiple Myeloma), $Million, 2022-2033
Figure 49: Global MRD Testing Market (Acute Lymphoblastic Leukemia), $Million, 2022-2033
Figure 50: Global MRD Testing Market (Chronic Lymphoblastic Leukemia), $Million, 2022-2033
Figure 51: Global MRD Testing Market (Acute Myeloid Leukemia), $Million, 2022-2033
Figure 52: Global MRD Testing Market (Chronic Myeloid Leukemia), $Million, 2022-2033
Figure 53: Global MRD Testing Market (Other Leukemia), $Million, 2022-2033
Figure 54: Global MRD Testing Market (Lymphoma), $Billion, 2022-2033
Figure 55: Global MRD Testing Market (Lymphoma), Units, 2022-2033
Figure 56: Global MRD Testing Market (Non-Hodgkin’s Lymphoma), $Million, 2022-2033
Figure 57: Global MRD Testing Market (HL), $Million, 2022-2033
Figure 58: Global MRD Testing Market (Solid Tumor), $Billion, 2022-2033
Figure 59: Global MRD Testing Market (Solid Tumor), Units, 2022-2033
Figure 60: Global MRD Testing Market (Colorectal Cancer), $Million, 2022-2033
Figure 61: Global MRD Testing Market (Breast Cancer), $Million, 2022-2033
Figure 62: Global MRD Testing Market (Lung Cancer), $Million, 2022-2033
Figure 63: Global MRD Testing Market (Other Cancer), $Million, 2022-2033
Figure 64: Global MRD Testing Market (by End User), $Billion, 2022-2033
Figure 65: Global MRD Testing Market (Hospitals and Specialty Clinics), $Billion, 2022-2033
Figure 66: Global MRD Testing Market (Hospitals and Specialty Clinics), Units, 2022-2033
Figure 67: Global MRD Testing Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 68: Global MRD Testing Market (Diagnostic Laboratories), Units, 2022-2033
Figure 69: Global MRD Testing Market (Research Institutions), $Billion, 2022-2033
Figure 70: Global MRD Testing Market (Research Institutions), Units, 2022-2033
Figure 71: Global MRD Testing Market (Others), $Billion, 2022-2033
Figure 72: Global MRD Testing Market (Others), Units, 2022-2033
Figure 73: Global MRD Testing Market Snapshot (by Region)
Figure 74: North America MRD Testing Market, $Billion, 2023-2033
Figure 75: North America: Market Dynamics
Figure 76: North America MRD Testing Market (by End User), $Million, 2022-2033
Figure 77: North America MRD Testing Market (by Country), $Million, 2022-2033
Figure 78: U.S. MRD Testing Market, $Million, 2022-2033
Figure 79: Canada MRD Testing Market, $Million, 2022-2033
Figure 80: Europe MRD Testing Market, $Billion, 2022-2033
Figure 81: Europe: Market Dynamics
Figure 82: Europe MRD Testing Market (by End User), $Million, 2022-2033
Figure 83: Europe MRD Testing Market (by Country), $Million, 2022-2033
Figure 84: Germany MRD Testing Market, $Million, 2022-2033
Figure 85: France MRD Testing Market, $Million, 2022-2033
Figure 86: U.K. MRD Testing Market, $Million, 2022-2033
Figure 87: Italy MRD Testing Market, $Million, 2022-2033
Figure 88: Spain MRD Testing Market, $Million, 2022-2033
Figure 89: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
Figure 90: Asia-Pacific: Market Dynamics
Figure 91: Asia-Pacific MRD Testing Market, $Billion, 2022-2033
Figure 92: Asia-Pacific MRD Testing Market (by End User), $Million, 2022-2033
Figure 93: Asia-Pacific MRD Testing Market (by Country), $Million, 2022-2033
Figure 94: China MRD Testing Market, $Million, 2022-2033
Figure 95: India MRD Testing Market, $Million, 2022-2033
Figure 96: Japan MRD Testing Market, $Million, 2022-2033
Figure 97: South Korea MRD Testing Market, $Million, 2022-2033
Figure 98: Australia MRD Testing Market, $Million, 2022-2033
Figure 99: Singapore MRD Testing Market, $Million, 2022-2033
Figure 100: Rest-of-Asia-Pacific MRD Testing Market, $Million, 2022-2033
Figure 101: Latin America: Market Dynamics
Figure 102: Latin-America and Middle East MRD Testing Market, $Billion, 2022-2033
Figure 103: Latin America and Middle East MRD Testing Market (by End User), $Million, 2022-2033
Figure 104: Latin America and Middle East MRD Testing Market (by Country), $Million, 2022-2033
Figure 105: Brazil MRD Testing Market, $Million, 2022-2033
Figure 106: Mexico MRD Testing Market, $Million, 2022-2033
Figure 107: Saudi Arabia MRD Testing Market, $Million, 2022-2033
Figure 108: Rest-of-Latin America and Middle East MRD Testing Market, $Million, 2022-2033
Figure 109: Rest-of-the-World MRD Testing Market, $Billion, 2022-2033
Figure 110: Rest-of-the-World MRD Testing Market (by End User), $Million, 2022-2033
Figure 111: Global MRD Testing Market, Total Number of Companies Profiled
Figure 112: Adaptive Biotechnologies: Product Portfolio
Figure 113: Adaptive Biotechnologies: Overall Financials, $Million, 2020-2022
Figure 114: Adaptive Biotechnologies: Revenue (by Segment), $Million, 2021-2022
Figure 115: Adaptive Biotechnologies: R&D Expenditure, $Million, 2020-2022
Figure 116: ARUP Laboratories: Product Portfolio
Figure 117: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 118: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 119: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 120: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 121: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 122: Cergentis B.V.: Product Portfolio
Figure 123: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 124: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 125: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 126: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 127: Guardant Health, Inc.: Product Portfolio
Figure 128: Guardant Health, Inc.: Overall Financials, $Million, 2020-2022
Figure 129: Guardant Health, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 130: Guardant Health, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 131: Guardant Health, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 132: Invivoscribe, Inc.: Product Portfolio
Figure 133: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 134: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 135: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 136: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 137: Mission Bio, Inc.: Product Portfolio
Figure 138: ICON plc: Product Portfolio
Figure 139: ICON plc: Overall Financials, $Million, 2019-2021
Figure 140: ICON plc: Revenue (by Region), $Million, 2019-2021
Figure 141: Natera, Inc.: Portfolio
Figure 142: Natera, Inc.: Overall Financials, $Million, 2020-2022
Figure 143: Natera, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 144: Natera, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 145: Natera, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 146: NeoGenomics Laboratories, Inc.: Portfolio
Figure 147: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 148: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 149: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 150: OPKO Health, Inc.: Product Portfolio
Figure 151: OPKO Health, Inc.: Overall Financials, $Million, 2020-2022
Figure 152: OPKO Health, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 153: OPKO Health, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 154: Quest Diagnostics Incorporated.: Product Portfolio
Figure 155: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
Figure 156: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2020-2022
Figure 157: Sysmex Corporation: Product Portfolio
Figure 158: Sysmex Corporation: Overall Financials, $Million, 2020-2022
Figure 159: Sysmex Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 160: Sysmex Corporation: Revenue (by Region), $Million, 2020-2022
Figure 161: Sysmex Corporation: R&D Expenditure, $Million, 2020-2022
Figure 1: Global MRD Testing Market, $Billion, 2022 and 2033
Figure 2: Share of Global MRD Testing Market (by Technology), $Billion, 2022 and 2033
Figure 3: Share of Global MRD Testing Market (by Target Detection), $Billion, 2022 and 2033
Figure 4: Share of Global MRD Testing Market (by End User), $Billion, 2022 and 2033
Figure 5: Share of Global MRD Testing Market (by Region), 2022
Figure 6: Global MRD Testing Market Segmentation
Figure 7: Global MRD Testing Market: Research Methodology
Figure 8: Primary Research Methodology
Figure 9: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Top-Down Approach (Segment-Wise Analysis)
Figure 11: MRD Testing Workflow
Figure 12: Evolution of the MRD Testing Market
Figure 13: Global MRD Testing Market Potential, $Billion, 2022-2033
Figure 14: Biomarker Evaluation and Evidentiary Considerations
Figure 15: Regulatory Submissions for the Use of Minimal Residual Disease as a Biomarker
Figure 16: Laboratory Methods for MRD Detection
Figure 17: Methods to Achieve Coverage
Figure 18: Supply Chain Analysis of Laboratory-Developed Tests
Figure 19: Supply Chain Analysis of In-Vitro Diagnostics
Figure 20: Global MRD Testing Market Dynamics
Figure 21: Growth of MRD Solutions Showcasing Increasing Number of Tests
Figure 22: Estimated New Cancer Cases and Deaths in the U.S., 2022
Figure 23: Patents Related to Companion Diagnostics Products Involved in MRD Testing, 2019-2023
Figure 24: Clinical Trials Undertaken by Adaptive Biotechnologies for MRD Testing, 2022
Figure 25: Share of Key Developments and Strategies, January 2020-May 2023
Figure 26: Share of Synergistic Activities (by Company), January 2020- May 2023
Figure 27: Share of Product Launches and Product Approvals (by Company), January 2020- May 2023
Figure 28: Share of Business Expansion (by Company), January 2020-May 2023
Figure 29: Merger and Acquisition (by Company), January 2020- May 2023
Figure 30: Share of Funding and Other Activities (by Company), January 2020- May 2023
Figure 31: Global MRD Testing Market, Company Share Analysis, 2022
Figure 32: Global MRD Testing Market, Growth Share Analysis, (by Technology), 2023-2033
Figure 33: Global MRD Testing Market (by Technology), $Billion, 2022-2033
Figure 34: MRD Detection by Multiparametric Flow Cytometry (MFC)
Figure 35: Global MRD Testing Market (Flow Cytometry), $Billion, 2022-2033
Figure 36: Global MRD Testing Market (Flow Cytometry), Thousand Units, 2022-2033
Figure 37: Global Minimal Residual Disease Testing Market (PCR), $Billion, 2022-2033
Figure 38: Global MRD Testing Market (PCR), Thousand Units, 2022-2033
Figure 39: Global MRD Testing Market (NGS), $Billion, 2022-2033
Figure 40: High-Throughput Sequencing Workflow for MRD Monitoring
Figure 41: Global MRD Testing Market (NGS), Thousand Units, 2022-2033
Figure 42: Global MRD Testing Market (Other Technologies), $Billion, 2022-2033
Figure 43: Global MRD Testing Market (Other Technologies), Thousand Units, 2022-2033
Figure 44: Global MRD Testing Market (by Target Detection)
Figure 45: Global MRD Testing Market (by Target Detection), $Billion, 2022-2033
Figure 46: Global MRD Testing Market (Leukemia), $Billion, 2022-2033
Figure 47: Global MRD Testing Market (Leukemia), Units, 2022-2033
Figure 48: Global MRD Testing Market (Multiple Myeloma), $Million, 2022-2033
Figure 49: Global MRD Testing Market (Acute Lymphoblastic Leukemia), $Million, 2022-2033
Figure 50: Global MRD Testing Market (Chronic Lymphoblastic Leukemia), $Million, 2022-2033
Figure 51: Global MRD Testing Market (Acute Myeloid Leukemia), $Million, 2022-2033
Figure 52: Global MRD Testing Market (Chronic Myeloid Leukemia), $Million, 2022-2033
Figure 53: Global MRD Testing Market (Other Leukemia), $Million, 2022-2033
Figure 54: Global MRD Testing Market (Lymphoma), $Billion, 2022-2033
Figure 55: Global MRD Testing Market (Lymphoma), Units, 2022-2033
Figure 56: Global MRD Testing Market (Non-Hodgkin’s Lymphoma), $Million, 2022-2033
Figure 57: Global MRD Testing Market (HL), $Million, 2022-2033
Figure 58: Global MRD Testing Market (Solid Tumor), $Billion, 2022-2033
Figure 59: Global MRD Testing Market (Solid Tumor), Units, 2022-2033
Figure 60: Global MRD Testing Market (Colorectal Cancer), $Million, 2022-2033
Figure 61: Global MRD Testing Market (Breast Cancer), $Million, 2022-2033
Figure 62: Global MRD Testing Market (Lung Cancer), $Million, 2022-2033
Figure 63: Global MRD Testing Market (Other Cancer), $Million, 2022-2033
Figure 64: Global MRD Testing Market (by End User), $Billion, 2022-2033
Figure 65: Global MRD Testing Market (Hospitals and Specialty Clinics), $Billion, 2022-2033
Figure 66: Global MRD Testing Market (Hospitals and Specialty Clinics), Units, 2022-2033
Figure 67: Global MRD Testing Market (Diagnostic Laboratories), $Billion, 2022-2033
Figure 68: Global MRD Testing Market (Diagnostic Laboratories), Units, 2022-2033
Figure 69: Global MRD Testing Market (Research Institutions), $Billion, 2022-2033
Figure 70: Global MRD Testing Market (Research Institutions), Units, 2022-2033
Figure 71: Global MRD Testing Market (Others), $Billion, 2022-2033
Figure 72: Global MRD Testing Market (Others), Units, 2022-2033
Figure 73: Global MRD Testing Market Snapshot (by Region)
Figure 74: North America MRD Testing Market, $Billion, 2023-2033
Figure 75: North America: Market Dynamics
Figure 76: North America MRD Testing Market (by End User), $Million, 2022-2033
Figure 77: North America MRD Testing Market (by Country), $Million, 2022-2033
Figure 78: U.S. MRD Testing Market, $Million, 2022-2033
Figure 79: Canada MRD Testing Market, $Million, 2022-2033
Figure 80: Europe MRD Testing Market, $Billion, 2022-2033
Figure 81: Europe: Market Dynamics
Figure 82: Europe MRD Testing Market (by End User), $Million, 2022-2033
Figure 83: Europe MRD Testing Market (by Country), $Million, 2022-2033
Figure 84: Germany MRD Testing Market, $Million, 2022-2033
Figure 85: France MRD Testing Market, $Million, 2022-2033
Figure 86: U.K. MRD Testing Market, $Million, 2022-2033
Figure 87: Italy MRD Testing Market, $Million, 2022-2033
Figure 88: Spain MRD Testing Market, $Million, 2022-2033
Figure 89: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
Figure 90: Asia-Pacific: Market Dynamics
Figure 91: Asia-Pacific MRD Testing Market, $Billion, 2022-2033
Figure 92: Asia-Pacific MRD Testing Market (by End User), $Million, 2022-2033
Figure 93: Asia-Pacific MRD Testing Market (by Country), $Million, 2022-2033
Figure 94: China MRD Testing Market, $Million, 2022-2033
Figure 95: India MRD Testing Market, $Million, 2022-2033
Figure 96: Japan MRD Testing Market, $Million, 2022-2033
Figure 97: South Korea MRD Testing Market, $Million, 2022-2033
Figure 98: Australia MRD Testing Market, $Million, 2022-2033
Figure 99: Singapore MRD Testing Market, $Million, 2022-2033
Figure 100: Rest-of-Asia-Pacific MRD Testing Market, $Million, 2022-2033
Figure 101: Latin America: Market Dynamics
Figure 102: Latin-America and Middle East MRD Testing Market, $Billion, 2022-2033
Figure 103: Latin America and Middle East MRD Testing Market (by End User), $Million, 2022-2033
Figure 104: Latin America and Middle East MRD Testing Market (by Country), $Million, 2022-2033
Figure 105: Brazil MRD Testing Market, $Million, 2022-2033
Figure 106: Mexico MRD Testing Market, $Million, 2022-2033
Figure 107: Saudi Arabia MRD Testing Market, $Million, 2022-2033
Figure 108: Rest-of-Latin America and Middle East MRD Testing Market, $Million, 2022-2033
Figure 109: Rest-of-the-World MRD Testing Market, $Billion, 2022-2033
Figure 110: Rest-of-the-World MRD Testing Market (by End User), $Million, 2022-2033
Figure 111: Global MRD Testing Market, Total Number of Companies Profiled
Figure 112: Adaptive Biotechnologies: Product Portfolio
Figure 113: Adaptive Biotechnologies: Overall Financials, $Million, 2020-2022
Figure 114: Adaptive Biotechnologies: Revenue (by Segment), $Million, 2021-2022
Figure 115: Adaptive Biotechnologies: R&D Expenditure, $Million, 2020-2022
Figure 116: ARUP Laboratories: Product Portfolio
Figure 117: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 118: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 119: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 120: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 121: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 122: Cergentis B.V.: Product Portfolio
Figure 123: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 124: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 125: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 126: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 127: Guardant Health, Inc.: Product Portfolio
Figure 128: Guardant Health, Inc.: Overall Financials, $Million, 2020-2022
Figure 129: Guardant Health, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 130: Guardant Health, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 131: Guardant Health, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 132: Invivoscribe, Inc.: Product Portfolio
Figure 133: Laboratory Corporation of America Holdings.: Product Portfolio
Figure 134: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
Figure 135: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
Figure 136: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
Figure 137: Mission Bio, Inc.: Product Portfolio
Figure 138: ICON plc: Product Portfolio
Figure 139: ICON plc: Overall Financials, $Million, 2019-2021
Figure 140: ICON plc: Revenue (by Region), $Million, 2019-2021
Figure 141: Natera, Inc.: Portfolio
Figure 142: Natera, Inc.: Overall Financials, $Million, 2020-2022
Figure 143: Natera, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 144: Natera, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 145: Natera, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 146: NeoGenomics Laboratories, Inc.: Portfolio
Figure 147: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2020-2022
Figure 148: NeoGenomics Laboratories, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 149: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 150: OPKO Health, Inc.: Product Portfolio
Figure 151: OPKO Health, Inc.: Overall Financials, $Million, 2020-2022
Figure 152: OPKO Health, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 153: OPKO Health, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 154: Quest Diagnostics Incorporated.: Product Portfolio
Figure 155: Quest Diagnostics Incorporated: Overall Financials, $Million, 2020-2022
Figure 156: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2020-2022
Figure 157: Sysmex Corporation: Product Portfolio
Figure 158: Sysmex Corporation: Overall Financials, $Million, 2020-2022
Figure 159: Sysmex Corporation: Revenue (by Segment), $Million, 2020-2022
Figure 160: Sysmex Corporation: Revenue (by Region), $Million, 2020-2022
Figure 161: Sysmex Corporation: R&D Expenditure, $Million, 2020-2022
LIST OF TABLES
Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Global MRD Testing Market
Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
Table 3: Comparison of FDA and EMA Draft Guidance
Table 4: Registration Criteria for IVD Medical Devices as per CFDA
Table 5: Key Coverage Providers for Hematologic Malignancies Testing
Table 6: Products used for Solid Tumor MRD Diagnosis
Table 7: Expansion of Medicare Coverage for MRD Tests by Companies
Table 8: Classification of MRD Test Results by True Relapse State Without Further Treatment in 2019
Table 9: Average Price of MRD Testing
Table 10: Comparison of Different Methods for Minimal Residual Disease Testing
Table 11: Key Products Offered by Companies Based on Flow Cytometry
Table 12: Key Products Offered by the Companies Based on PCR
Table 13: Key Products Offered by Companies Based on NGS
Table 14: Ongoing Initiatives to Generate Evidence for MRD Test in AML Patients
Table 15: Molecular Techniques used for MRD Assessment in NHL Patients
Table 16: Few Examples of Facilities Conducting MRD Testing
Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Global MRD Testing Market
Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
Table 3: Comparison of FDA and EMA Draft Guidance
Table 4: Registration Criteria for IVD Medical Devices as per CFDA
Table 5: Key Coverage Providers for Hematologic Malignancies Testing
Table 6: Products used for Solid Tumor MRD Diagnosis
Table 7: Expansion of Medicare Coverage for MRD Tests by Companies
Table 8: Classification of MRD Test Results by True Relapse State Without Further Treatment in 2019
Table 9: Average Price of MRD Testing
Table 10: Comparison of Different Methods for Minimal Residual Disease Testing
Table 11: Key Products Offered by Companies Based on Flow Cytometry
Table 12: Key Products Offered by the Companies Based on PCR
Table 13: Key Products Offered by Companies Based on NGS
Table 14: Ongoing Initiatives to Generate Evidence for MRD Test in AML Patients
Table 15: Molecular Techniques used for MRD Assessment in NHL Patients
Table 16: Few Examples of Facilities Conducting MRD Testing
